Median time to treatment was 39 days for ACCELERATE cohort versus 62 days for reference cohort using standard tissue genotyping
About 15 percent of patients diagnosed with lung cancer had PGVs, most of which were potentially clinically actionable
Objective response seen in 37.1 percent of patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer
Mutation frequencies of <em>EGFR</em> and <em>KRAS</em> were 30 and 10 percent, respectively, and 23 and 13 percent, respectively, for Mexican and Colombian patients